• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Adding Recognition Discriminability Index to the Delayed Recall Is Useful to Predict Conversion from Mild Cognitive Impairment to Alzheimer's Disease in the Alzheimer's Disease Neuroimaging Initiative.在阿尔茨海默病神经影像倡议中,将识别辨别指数添加到延迟回忆中有助于预测从轻度认知障碍向阿尔茨海默病的转化。
Front Aging Neurosci. 2017 Mar 10;9:46. doi: 10.3389/fnagi.2017.00046. eCollection 2017.
2
Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia.生物标志物组合对预测轻度认知障碍向阿尔茨海默病痴呆进展的增量价值。
Alzheimers Res Ther. 2017 Oct 10;9(1):84. doi: 10.1186/s13195-017-0301-7.
3
Predictive value for cerebrospinal fluid Alzheimer's disease profile of different measures of verbal episodic memory in patients with MCI.不同言语情景记忆测量指标在 MCI 患者中对脑脊液阿尔茨海默病谱的预测价值。
Sci Rep. 2024 May 28;14(1):12235. doi: 10.1038/s41598-024-62604-z.
4
Neuropsychological predictors of conversion from mild cognitive impairment to Alzheimer's disease.从轻度认知障碍到阿尔茨海默病的神经心理学预测因素。
J Alzheimers Dis. 2014;38(3):481-95. doi: 10.3233/JAD-130881.
5
Harnessing forgetfulness: can episodic-memory tests predict early Alzheimer's disease?利用遗忘:情景记忆测试能否预测早期阿尔茨海默病?
Exp Brain Res. 2021 Sep;239(9):2925-2937. doi: 10.1007/s00221-021-06182-w. Epub 2021 Jul 27.
6
Diagnostic and Prognostic Value of the Combination of Two Measures of Verbal Memory in Mild Cognitive Impairment due to Alzheimer's Disease.两种言语记忆测量方法联合应用对阿尔茨海默病所致轻度认知障碍的诊断及预后价值
J Alzheimers Dis. 2017;58(3):909-918. doi: 10.3233/JAD-170073.
7
Integration and relative value of biomarkers for prediction of MCI to AD progression: spatial patterns of brain atrophy, cognitive scores, APOE genotype and CSF biomarkers.用于预测轻度认知障碍(MCI)向阿尔茨海默病(AD)进展的生物标志物的整合与相对价值:脑萎缩的空间模式、认知评分、载脂蛋白E(APOE)基因型和脑脊液生物标志物
Neuroimage Clin. 2013 Nov 28;4:164-73. doi: 10.1016/j.nicl.2013.11.010. eCollection 2014.
8
Predicting progression to Alzheimer's disease in subjects with amnestic mild cognitive impairment using performance on recall and recognition tests.使用回忆和识别测试的表现预测遗忘型轻度认知障碍患者向阿尔茨海默病的进展。
J Neurol. 2019 Jan;266(1):102-111. doi: 10.1007/s00415-018-9108-0. Epub 2018 Nov 1.
9
Development and assessment of a composite score for memory in the Alzheimer's Disease Neuroimaging Initiative (ADNI).发展和评估阿尔茨海默病神经影像学倡议 (ADNI) 中记忆的综合评分。
Brain Imaging Behav. 2012 Dec;6(4):502-16. doi: 10.1007/s11682-012-9186-z.
10
Varying strength of cognitive markers and biomarkers to predict conversion and cognitive decline in an early-stage-enriched mild cognitive impairment sample.在一个早期富集的轻度认知障碍样本中,用于预测转化和认知衰退的认知标志物和生物标志物的不同强度。
J Alzheimers Dis. 2015;44(2):625-33. doi: 10.3233/JAD-141716.

引用本文的文献

1
Posterior hippocampal sparing in Lewy body disorders with Alzheimer's copathology: An in vivo MRI study.路易体疾病合并阿尔茨海默病共同病理改变时海马后部的保留:一项活体MRI研究
Neuroimage Clin. 2025;45:103714. doi: 10.1016/j.nicl.2024.103714. Epub 2024 Dec 7.
2
Argentina-Alzheimer's Disease Neuroimaging Initiative: pioneering Alzheimer's Research in Latin America and its Implications for Regional Advancement.阿根廷-阿尔茨海默病神经影像学倡议:拉丁美洲开创性的阿尔茨海默病研究及其对区域发展的影响。
Alzheimers Dement. 2024 Nov;20(11):8153-8161. doi: 10.1002/alz.14285. Epub 2024 Oct 6.
3
Process approach as a cognitive biomarker related to gray matter volume in mild cognitive impairment and Alzheimer's disease.过程方法作为一种认知生物标志物,与轻度认知障碍和阿尔茨海默病的灰质体积有关。
BMC Neurol. 2024 Jun 13;24(1):199. doi: 10.1186/s12883-024-03711-2.
4
Predictors and prognosis of population-based subjective cognitive decline: longitudinal evidence from the Caerphilly Prospective Study (CaPS).基于人群的主观认知衰退的预测因素和预后:来自卡菲利前瞻性研究 (CaPS) 的纵向证据。
BMJ Open. 2023 Oct 16;13(10):e073205. doi: 10.1136/bmjopen-2023-073205.
5
Cognitive inhibition abilities explain inter-individual variability in gender-space associations.认知抑制能力解释了性别与空间关联中的个体间差异。
Front Psychol. 2023 May 17;14:1130105. doi: 10.3389/fpsyg.2023.1130105. eCollection 2023.
6
Trajectories of Cognitive Impairment in Adults Bearing Vascular Risk Factors, with or without Diagnosis of Mild Cognitive Impairment: Findings from a Longitudinal Study Assessing Executive Functions, Memory, and Social Cognition.患有血管危险因素的成年人(无论是否诊断为轻度认知障碍)认知障碍的轨迹:一项评估执行功能、记忆和社会认知的纵向研究结果
Diagnostics (Basel). 2022 Dec 2;12(12):3017. doi: 10.3390/diagnostics12123017.
7
Clockwise rotation of perspective view improves spatial recognition of complex environments in aging.顺时针旋转视角可改善老年人对复杂环境的空间认知。
Sci Rep. 2022 Nov 5;12(1):18756. doi: 10.1038/s41598-022-23301-x.
8
Recall and recognition subtests of the repeatable battery for the assessment of neuropsychological status and their relationship to biomarkers of Alzheimer's disease.可重复神经心理状态评估测验的回忆和识别子测验及其与阿尔茨海默病生物标志物的关系。
Neuropsychol Dev Cogn B Aging Neuropsychol Cogn. 2023 Sep-Nov;30(6):885-902. doi: 10.1080/13825585.2022.2124229. Epub 2022 Sep 15.
9
Modulation of entorhinal cortex-hippocampus connectivity and recognition memory following electroacupuncture on 3×Tg-AD model: Evidence from multimodal MRI and electrophysiological recordings.电针对3×Tg-AD模型内嗅皮层-海马连接及识别记忆的调节作用:来自多模态磁共振成像和电生理记录的证据
Front Neurosci. 2022 Jul 29;16:968767. doi: 10.3389/fnins.2022.968767. eCollection 2022.
10
Neuropsychological, neuropsychiatric, and quality-of-life assessments in Alzheimer's disease patients treated with plasma exchange with albumin replacement from the randomized AMBAR study.阿尔茨海默病患者接受白蛋白置换的血浆置换治疗后的神经心理学、神经精神和生活质量评估:来自随机 AMBAR 研究的结果。
Alzheimers Dement. 2022 Jul;18(7):1314-1324. doi: 10.1002/alz.12477. Epub 2021 Nov 2.

本文引用的文献

1
Usefulness of Discriminability and Response Bias Indices for the Evaluation of Recognition Memory in Mild Cognitive Impairment and Alzheimer Disease.辨别力和反应偏差指数在轻度认知障碍和阿尔茨海默病识别记忆评估中的效用
Dement Geriatr Cogn Disord. 2017;43(1-2):1-14. doi: 10.1159/000452255. Epub 2016 Nov 26.
2
Neuropsychological predictors of conversion from mild cognitive impairment to Alzheimer's disease.从轻度认知障碍到阿尔茨海默病的神经心理学预测因素。
J Alzheimers Dis. 2014;38(3):481-95. doi: 10.3233/JAD-130881.
3
Screening for predementia AD: time-dependent operating characteristics of episodic memory tests.痴呆前期 AD 的筛查:情景记忆测验的时间依赖性操作特征。
Neurology. 2013 Apr 2;80(14):1307-14. doi: 10.1212/WNL.0b013e31828ab2c9. Epub 2013 Mar 6.
4
The neuropsychological profile of Alzheimer disease.阿尔茨海默病的神经心理学特征。
Cold Spring Harb Perspect Med. 2012 Apr;2(4):a006171. doi: 10.1101/cshperspect.a006171.
5
Utility of combinations of biomarkers, cognitive markers, and risk factors to predict conversion from mild cognitive impairment to Alzheimer disease in patients in the Alzheimer's disease neuroimaging initiative.阿尔茨海默病神经影像倡议中生物标志物、认知标志物和风险因素组合对预测轻度认知障碍患者向阿尔茨海默病转化的效用
Arch Gen Psychiatry. 2011 Sep;68(9):961-9. doi: 10.1001/archgenpsychiatry.2011.96.
6
The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.阿尔茨海默病所致轻度认知障碍的诊断:美国国家老龄化研究所-阿尔茨海默病协会诊断指南工作组的建议。
Alzheimers Dement. 2011 May;7(3):270-9. doi: 10.1016/j.jalz.2011.03.008. Epub 2011 Apr 21.
7
Category cued recall following controlled encoding as a neuropsychological tool in the diagnosis of Alzheimer's disease: a review of the evidence.类别线索回忆法在阿尔茨海默病诊断中的神经心理学工具作用:证据综述。
Neuropsychol Rev. 2011 Mar;21(1):54-65. doi: 10.1007/s11065-010-9153-7. Epub 2010 Nov 18.
8
Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization.阿尔茨海默病神经影像学倡议(ADNI):临床特征。
Neurology. 2010 Jan 19;74(3):201-9. doi: 10.1212/WNL.0b013e3181cb3e25. Epub 2009 Dec 30.
9
Cerebrospinal fluid biomarkers and prediction of conversion in patients with mild cognitive impairment: 4-year follow-up in a routine clinical setting.脑脊液生物标志物与轻度认知障碍患者病情转化的预测:常规临床环境下的4年随访
ScientificWorldJournal. 2009 Sep 15;9:961-6. doi: 10.1100/tsw.2009.106.
10
Progression of mild cognitive impairment to dementia in clinic- vs community-based cohorts.临床队列与社区队列中轻度认知障碍向痴呆症的进展
Arch Neurol. 2009 Sep;66(9):1151-7. doi: 10.1001/archneurol.2009.106.

在阿尔茨海默病神经影像倡议中,将识别辨别指数添加到延迟回忆中有助于预测从轻度认知障碍向阿尔茨海默病的转化。

Adding Recognition Discriminability Index to the Delayed Recall Is Useful to Predict Conversion from Mild Cognitive Impairment to Alzheimer's Disease in the Alzheimer's Disease Neuroimaging Initiative.

作者信息

Russo María J, Campos Jorge, Vázquez Silvia, Sevlever Gustavo, Allegri Ricardo F

机构信息

Author Affiliations: UC San Francisco; University of Southern California; UC San Francisco University of Southern California Mayo Clinic, Rochester Mayo Clinic, Rochester; UC Berkeley; U Pennsylvania; USC; UC Davis; Brigham and Women's Hospital/Harvard Medical School Indiana University Washington University St. Louis University of Pennsylvania; Prevent Alzheimer's Disease 2020 (Chair) Siemens; Alzheimer's Association University of Pittsburgh Washington University St. Louis Cornell University; Albert Einstein College of Medicine of Yeshiva University; AD Drug Discovery Foundation; Acumen Pharmaceuticals; Washington University St. Louis; Northwestern University; National Institute of Mental Health; Brown University; Eli Lilly (Chair); BWH/HMS (Chair); University of Washington (Chair); Mayo Clinic, Rochester (Core PI) University of Southern California; UC San Diego; UC San Diego; UC San Diego; UC San Diego; UC San Diego; UC San Diego; UC San Diego; UC San Diego; UC San Diego; UC Davis (Core PI); UC Davis; UC San Diego; Mayo Clinic, Rochester (Core PI); Mayo Clinic, Rochester; University of London; UCLA School of Medicine; UCSF MRI; UC Davis; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; UC Berkeley (Core PI); University of Michigan; University of Utah; Banner Alzheimer's Institute; Banner Alzheimer's Institute; University of Pittsburgh; UC Berkeley; Washington University St. Louis; Washington University St. Louis; Washington University St. Louis; Washington University St. Louis; UPenn School of Medicine; UPenn School of Medicine; UPenn School of Medicine; UPenn School of Medicine; UPenn School of Medicine; USC (Core PI); USC; USC; Indiana University; Indiana University; UC Irvine; Indiana University; Indiana University; Indiana University; Indiana University; UC San Francisco; UC San Diego; Prevent Alzheimer's Disease 2020; UC San Diego; National Institute on Aging; UC San Francisco; Brown University; National Institute of Mental Health; Cornell University; Johns Hopkins University; Richard Frank Consulting; Prevent Alzheimer's Disease 2020; National Institute on Aging; Oregon Health & Science University; University of Southern California; University of California - San Diego; University of Michigan; Mayo Clinic, Rochester; Baylor College of Medicine; Columbia University Medical Center; Washington University, St. Louis; University of Alabama - Birmingham; Mount Sinai School of Medicine; Rush University Medical Center; Wien Center; Johns Hopkins University; New York University; Duke University Medical Center; University of Pennsylvania; University of Kentucky; University of Pittsburgh; University of Rochester Medical Center; University of California, Irvine; University of Texas Southwestern Medical School; Emory University; University of Kansas, Medical Center; University of California, Los Angeles; Mayo Clinic, Jacksonville; Indiana University; Yale University School of Medicine; McGill Univ., Montreal-Jewish General Hospital; Sunnybrook Health Sciences, Ontario; U.B.C. Clinic for AD & Related Disorders; Cognitive Neurology - St. Joseph's, Ontario; Cleveland Clinic Lou Ruvo Center for Brain Health; Northwestern University; Premiere Research Inst (Palm Beach Neurology); Georgetown University Medical Center; Brigham and Women's Hospital; Stanford University; Banner Sun Health Research Institute; Boston University; Howard University; Case Western Reserve University; University of California, Davis - Sacramento; Neurological Care of CNY; Parkwood Hospital; University of Wisconsin; University of California, Irvine - BIC; Banner Alzheimer's Institute; Dent Neurologic Institute; Ohio State University; Albany Medical College; Hartford Hospital, Olin Neuropsychiatry Research Center; Dartmouth-Hitchcock Medical Center; Wake Forest University Health Sciences; Rhode Island Hospital; Butler Hospital; UC San Francisco; Medical University South Carolina; St. Joseph's Health Care; Nathan Kline Institute; University of Iowa College of Medicine; Cornell University; University of South Florida: USF Health Byrd Alzheimer's Institute; University of California, San Francisco; University of Southern California; UC San Francisco; University of Southern California; Mayo Clinic, Rochester; Brigham and Women's Hospital/ Harvard Medical School; UC Davis; Mayo Clinic, Rochester; UC Berkeley; Washington University St. Louis; Indiana University; Perelman School of Medicine, UPenn; USC; Perelman School of Medicine, University of Pennsylvania; UC San Francisco; Rehabilitation Institute of Chicago, Feinberg School of Medicine, Northwestern University; BWH/HMS (Chair); University of Washington (Chair); Core PI; Mayo Clinic, Rochester (Core PI); University of Southern California; UC San Diego; UC San Diego; UC San Diego; UC San Diego; UC San Diego; UC San Diego; UC San Diego; UC San Francisco; UC San Francisco; UC San Francisco; UC Davis (Core PI); UC San Diego; Mayo Clinic, Rochester (Core PI); Mayo Clinic, Rochester; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; UC Berkeley (Core PI); University of Michigan; University of Utah; Banner Alzheimer's Institute; Banner Alzheimer's Institute; UC Berkeley; Washington University St. Louis; Washington University St. Louis; Washington University St. Louis; Perelman School of Medicine, UPenn; Perelman School of Medicine, UPenn; Perelman School of Medicine, UPenn; Perelman School of Medicine, UPenn; Perelman School of Medicine, UPenn; USC (Core PI); USC; USC; Indiana University; Indiana University; UC Irvine; Indiana University; Indiana University; Indiana University; Indiana University; UC San Francisco; Department of Defense (retired); University of Southern California; University of California, San Diego; Columbia University Medical Center; Rush University Medical Center; Wien Center; Duke University Medical Center; University of Rochester Medical Center; University of California, Irvine; Medical University South Carolina; Premiere Research Inst (Palm Beach Neurology); University of California, San Francisco; Georgetown University Medical Center; Brigham and Women's Hospital; Banner Sun Health Research Institute; Howard University; University of Wisconsin; University of Washington; Stanford University; Cornell University.

出版信息

Front Aging Neurosci. 2017 Mar 10;9:46. doi: 10.3389/fnagi.2017.00046. eCollection 2017.

DOI:10.3389/fnagi.2017.00046
PMID:28344552
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5344912/
Abstract

Ongoing research is focusing on the identification of those individuals with mild cognitive impairment (MCI) who are most likely to convert to Alzheimer's disease (AD). We investigated whether recognition memory tasks in combination with delayed recall measure of episodic memory and CSF biomarkers can predict MCI to AD conversion at 24-month follow-up. A total of 397 amnestic-MCI subjects from Alzheimer's disease Neuroimaging Initiative were included. Logistic regression modeling was done to assess the predictive value of all RAVLT measures, risk factors such as age, sex, education, APOE genotype, and CSF biomarkers for progression to AD. Estimating adjusted odds ratios was used to determine which variables would produce an optimal predictive model, and whether adding tests of interaction between the RAVLT Delayed Recall and recognition measures (traditional score and d-prime) would improve prediction of the conversion from a-MCI to AD. 112 (28.2%) subjects developed dementia and 285 (71.8%) subjects did not. Of the all included variables, CSF Aβ1-42 levels, RAVLT Delayed Recall, and the combination of RAVLT Delayed Recall and d-prime were predictive of progression to AD (χ = 38.23, = 14, < 0.001). The combination of RAVLT Delayed Recall and d-prime measures may be predictor of conversion from MCI to AD in the ADNI cohort, especially in combination with amyloid biomarkers. A predictive model to help identify individuals at-risk for dementia should include not only traditional episodic memory measures (delayed recall or recognition), but also additional variables (d-prime) that allow the homogenization of the assessment procedures in the diagnosis of MCI.

摘要

正在进行的研究聚焦于识别那些最有可能转化为阿尔茨海默病(AD)的轻度认知障碍(MCI)个体。我们调查了识别记忆任务与情景记忆延迟回忆测量及脑脊液生物标志物相结合是否能预测24个月随访期内MCI向AD的转化。纳入了来自阿尔茨海默病神经影像倡议组织的397名遗忘型MCI受试者。进行逻辑回归建模以评估所有雷伊听觉词语学习测验(RAVLT)测量指标、年龄、性别、教育程度、载脂蛋白E(APOE)基因型等风险因素以及脑脊液生物标志物对进展为AD的预测价值。使用估计的调整比值比来确定哪些变量将产生最佳预测模型,以及添加RAVLT延迟回忆与识别测量(传统分数和d')之间的交互作用测试是否会改善从a-MCI向AD转化的预测。112名(28.2%)受试者发展为痴呆,285名(71.8%)受试者未发展为痴呆。在所有纳入的变量中,脑脊液淀粉样蛋白β1-42(Aβ1-42)水平、RAVLT延迟回忆以及RAVLT延迟回忆与d'的组合可预测进展为AD(χ = 38.23,自由度 = 14,P < 0.001)。在ADNI队列中,RAVLT延迟回忆与d'测量的组合可能是MCI向AD转化的预测指标,尤其是与淀粉样蛋白生物标志物相结合时。一个有助于识别痴呆风险个体的预测模型不仅应包括传统的情景记忆测量指标(延迟回忆或识别),还应包括其他变量(d'),这些变量可使MCI诊断中的评估程序同质化。